Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2014', provides an overview of the Neisseria Gonorrhoeae Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neisseria Gonorrhoeae Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neisseria Gonorrhoeae Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neisseria Gonorrhoeae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neisseria Gonorrhoeae Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neisseria Gonorrhoeae Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neisseria Gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neisseria Gonorrhoeae Infections Overview 7
Therapeutics Development 8
Pipeline Products for Neisseria Gonorrhoeae Infections - Overview 8
Pipeline Products for Neisseria Gonorrhoeae Infections - Comparative Analysis 9
Neisseria Gonorrhoeae Infections - Therapeutics under Development by Companies 10
Neisseria Gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 11
Neisseria Gonorrhoeae Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Neisseria Gonorrhoeae Infections - Products under Development by Companies 14
Neisseria Gonorrhoeae Infections - Products under Investigation by Universities/Institutes 15
Neisseria Gonorrhoeae Infections - Companies Involved in Therapeutics Development 16
Adenium Biotech ApS 16
AstraZeneca PLC 17
BioDiem Ltd 18
Biolytics Pharma 19
Debiopharm International S.A. 20
Durata Therapeutics, Inc. 21
Sumitomo Dainippon Pharma Co., Ltd. 22
Vertex Pharmaceuticals Incorporated 23
Neisseria Gonorrhoeae Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Arenicin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AZD-0914 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BDM-I - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cribrostatin-6 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
dalbavancin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Debio-1453 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
gonorrhoeae vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SM-295291 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SM-369926 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit Tubulin for Neuroblastoma and Neisseria Gonorrhoeae Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine for Neisseria Gonorrhoeae Infection - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VT-12008911 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Neisseria Gonorrhoeae Infections - Recent Pipeline Updates 48
Neisseria Gonorrhoeae Infections - Dormant Projects 57
Neisseria Gonorrhoeae Infections - Product Development Milestones 58
Featured News & Press Releases 58
Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 58
Jun 03, 2014: AstraZeneca's novel antibiotic candidate AZD0914 given Fast Track status by US FDA 60
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Neisseria Gonorrhoeae Infections, H2 2014 8
Number of Products under Development for Neisseria Gonorrhoeae Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Neisseria Gonorrhoeae Infections - Pipeline by Adenium Biotech ApS, H2 2014 16
Neisseria Gonorrhoeae Infections - Pipeline by AstraZeneca PLC, H2 2014 17
Neisseria Gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2014 18
Neisseria Gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2014 19
Neisseria Gonorrhoeae Infections - Pipeline by Debiopharm International S.A., H2 2014 20
Neisseria Gonorrhoeae Infections - Pipeline by Durata Therapeutics, Inc., H2 2014 21
Neisseria Gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 22
Neisseria Gonorrhoeae Infections - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Neisseria Gonorrhoeae Infections Therapeutics - Recent Pipeline Updates, H2 2014 48
Neisseria Gonorrhoeae Infections - Dormant Projects, H2 2014 57